NCT06603077 Phase 2 Completed
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa Study sponsor: Avalo Therapeutics, Inc. · AVTX
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2026-02-23 Actual
Enrollment · participants 253 Actual
Source updated 2026-04-21 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-04-21 · 3 fields changed
Participant count type changed
Enrollment · participant count changed
− Before 250 participants (planned)
+ After 253 participants (actual)
Recruitment status changed
− Before Active not recruiting
Check registry source
Posted 2026-03-25 · 2 fields changed
Completion date type changed
Primary completion date changed
Check registry source
Posted 2025-11-13 · 3 fields changed
Planned enrollment increased by 28 participants
− Before 222 participants (planned)
+ After 250 participants (planned)
Primary completion date changed
Recruitment status changed
+ After Active not recruiting
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial